Amgen stock (US0311621009): Piper Sandler cuts price target amid rare disease review

Piper Sandler lowered its Amgen price target to $427 from $432 while keeping an Overweight rating, citing rare disease outlook. Biotech reported strong Q4 2025 revenue beat.

Amgen Inc stock drew attention after Piper Sandler adjusted its price target downward to $427 from $432, maintaining an Overweight rating, due to updates on its rare disease portfolio, according to Investing.com. Separately, the company posted Q4 CY2025 revenue of $9.87 billion, up 8.6% year-over-year and beating estimates by 4.1%, with adjusted EPS of $5.15 surpassing forecasts.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Amgen Inc
• Sector/industry: Pharmaceuticals/Biotech
• Headquarters/country: United States
• Core markets: US, Europe, Global
• Key revenue drivers: Oncology, Inflammation, Rare Diseases
• Home exchange/listing venue: Nasdaq (AMGN)
• Trading currency: USD

Amgen Inc: core business model

Amgen Inc develops and markets human therapeutics targeting serious illnesses in oncology, inflammation, bone, cardiovascular, and rare diseases. The Nasdaq-listed biotech pioneered biologic therapies, with key products like Enbrel, Prolia, and Repatha driving revenue. Its model focuses on innovation through R&D investment, partnerships, and a robust pipeline of monoclonal antibodies and bispecific molecules.

Headquartered in Thousand Oaks, California, Amgen serves over 10 million patients globally, with the US accounting for more than 70% of sales. The company reported earnings growth of 31.5% over the past year, per Simply Wall St as of recent data.

Main revenue and product drivers for Amgen Inc

Amgen's top revenue generator is its oncology portfolio, including Kyprolis and Xgeva, contributing significantly to quarterly results. In Q4 CY2025, total revenue reached $9.87 billion, up 8.6% YoY, beating Wall Street estimates by 4.1%, according to StockStory. Adjusted EPS hit $5.15, an 8% beat over $4.77 consensus.

Blockbuster drugs like Prolia for osteoporosis and Enbrel for autoimmune conditions remain core, alongside newer entrants in cardiovascular and rare diseases. Full-year revenue for CY2025 was $8.62 billion in one reported quarter, with 5.8% YoY growth.

Industry trends and competitive position

The biotech sector faces patent cliffs and biosimilar competition, but Amgen's diversified pipeline positions it strongly. With a market cap of $181.58 billion as of March 20, 2026, per Stock Analysis as of 03/20/2026, it ranks among top players. Rivals include Eli Lilly and Regeneron, yet Amgen's beta of 0.44 indicates lower volatility.

Why Amgen Inc matters for US investors

Listed on Nasdaq, Amgen offers US investors exposure to high-growth biotech with substantial US market reliance. Its products address prevalent conditions like cancer and osteoporosis, aligning with aging demographics and healthcare spending trends in the world's largest pharma market.

Conclusion

Amgen Inc continues to deliver solid financials, as seen in its Q4 revenue beat and ongoing analyst coverage like Piper Sandler's adjusted target. With a strong product lineup and US-centric revenue, the stock remains a key watch for biotech enthusiasts. Market dynamics, including rare disease developments, will shape near-term performance amid broader sector trends.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.